Abstract:Airway microbiota are known to contribute to lung diseases, such as cystic fibrosis (CF), but their contributions to pathogenesis are still unclear. To improve our understanding of host-microbe interactions, we have developed an integrated analytical and bioinformatic mass spectrometry (MS)-based metaproteomics workflow to analyze clinical bronchoalveolar lavage (BAL) samples from people with airway disease. Proteins from BAL cellular pellets were processed and pooled together in groups categorized by disease status (CF vs. non-CF) and bacterial diversity, based on previously performed small subunit rRNA sequencing data. Proteins from each pooled sample group were digested and subjected to liquid chromatography tandem mass spectrometry (MS/MS). MS/MS spectra were matched to human and bacterial peptide sequences leveraging a bioinformatic workflow using a metagenomics-guided protein sequence database and rigorous evaluation. Label-free quantification revealed differentially abundant human peptides from proteins with known roles in CF, like neutrophil elastase and collagenase, and proteins with lesser-known roles in CF, including apolipoproteins. Differentially abundant bacterial peptides were identified from known CF pathogens (e.g., Pseudomonas), as well as other taxa with potentially novel roles in CF. We used this host-microbe peptide panel for targeted parallel-reaction monitoring validation, demonstrating for the first time an MS-based assay effective for quantifying host-microbe protein dynamics within BAL cells from individual CF patients. Our integrated bioinformatic and analytical workflow combining discovery, verification, and validation should prove useful for diverse studies to characterize microbial contributors in airway diseases. Furthermore, we describe a promising preliminary panel of differentially abundant microbe and host peptide sequences for further study as potential markers of host-microbe relationships in CF disease pathogenesis.IMPORTANCEIdentifying microbial pathogenic contributors and dysregulated human responses in airway disease, such as CF, is critical to understanding disease progression and developing more effective treatments. To this end, characterizing the proteins expressed from bacterial microbes and human host cells during disease progression can provide valuable new insights. We describe here a new method to confidently detect and monitor abundance changes of both microbe and host proteins from challenging BAL samples commonly collected from CF patients. Our method uses both state-of-the art mass spectrometry-based instrumentation to detect proteins present in these samples and customized bioinformatic software tools to analyze the data and characterize detected proteins and their association with CF. We demonstrate the use of this method to characterize microbe and host proteins from individual BAL samples, paving the way for a new approach to understand molecular contributors to CF and other diseases of the airway.

Development and qualification of an LC-MS/MS method for the quantification of MUC5AC and MUC5B mucins in spontaneous human sputum

Expression and Clinical Significance of Mucoprotein MUC5AC in Patients with Chronic Obstructive Pulmonary Disease

Ion mobility-tandem mass spectrometry of mucin-type O-glycans

Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD

LSC - 2024 - Mucin overexpression in (pre-)COPD lung tissue correlates with degree of emphysema

The Characteristics and Clinical Significance of Mucin Levels in Bronchoalveolar Lavage Fluid of Patients with Interstitial Lung Disease.

Genetic regulators of sputum mucin concentration and their associations with COPD phenotypes

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Systematic Study on a Quantitative Analysis of Multicomponents by Single Marker (QAMS) Method for Simultaneous Determination of Eight Constituents in Pneumonia Mixture by UPLC-MS/MS

Proteomic Analysis of Sputum Reveals Novel Biomarkers for Various Presentations of Asthma.

Sputum supernatant as a viable alternative for liquid biopsy in advanced non-small cell lung cancer.

Quantification of five antineoplastic agents in swab samples using UPLC-ESI-MS/MS: method development and validation

Expression of Mucin Family Proteins in Non-Small-Cell Lung Cancer and Its Role in Evaluation of Prognosis

Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum

An integrated metaproteomics workflow for studying host-microbe dynamics in bronchoalveolar lavage samples applied to cystic fibrosis disease

Sputum Proteomics reveals unique signatures linked to key outcomes in cystic fibrosis trials.

Mucus Structure, Viscoelastic Properties, and Composition in Chronic Respiratory Diseases

Design of a multi-center immunophenotyping analysis of peripheral blood, sputum and bronchoalveolar lavage fluid in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS)

Development and validation of LC-MS/MS methods for the quantification of 101BHG-D01, a novel, long-acting and selective muscarinic receptor antagonist, and its main metabolite M6 in human plasma, urine and feces: Application to a clinical study in healthy Chinese subjects

An integrated metabo-lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD

Evaluation of low volume sampling devices for a pharmacodynamic biomarker analysis: Challenges and solutions